Zoetis Q4 Sales Cushioned By Higher Companion Animal Product Sales, Issues FY22 Outlook

Zoetis Inc ZTS has reported Q4 FY21 revenue of $2 billion, an increase of 9% Y/Y, beating the consensus of $1.93 billion.

  • Adjusted EPS was $1.00, compared to $0.91 last year and beating the consensus of $0.96.
  • Revenue in the U.S. segment was $1.04 billion, +9%. Sales of companion animal products increased 20%, driven by growth across the Company's parasiticides portfolio. 
  • Sales of livestock products declined 13% due to generic competition for Draxxin and continued weakness in beef & dairy consumer markets. 
  • Also See: Zoetis Raises FY22 Dividend By 30%, Announces New Buyback Program Of $3.5B.
  • Poultry portfolio declined due to the expanded use of lower-cost alternatives and generic competition for Zoamix, the Company's option to antibiotics in medicated feed additives. 
  • Sales of swine products declined due to pricing pressure on anti-infectives and vaccines.
  • Revenue in the International segment increased 8% to $902 million.
  • Guidance: Zoetis expects FY22 sales of $8.325 billion - $8.475 billion, compared to the consensus of $8.41 billion.
  • It expects adjusted EPS of $5.09 - $5.19, lower than the consensus of $5.21.
  • Price Action: ZTS shares are up 2.22% at $200.80 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!